Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has demonstrated tolerability to test doses of oral aripiprazole during screening; OR has a history of tolerated use of aripiprazole
Has a diagnosis of schizophrenia
Is clinically stable
Has received at least 3 doses of risperidone long acting injection (Risperdal Consta) or paliperidone palmitate (Invega Sustenna) prior to screening.
Has no antipsychotic medication regimen change for 4 weeks prior to Day 1
Agreed to abide by the contraceptive requirements o the protocol
Resides in a stable living situation
Additional criteria may apply
You may not be if
Is currently pregnant or breastfeeding, or is planning to become pregnant during the study
Has received Invega Trinza, aripiprazole lauroxil, or IM depot aripiprazole within 6 months of screening
Has participated in a clinical trial involving any investigational product within the past 3 months, or is currently participating in a clinical trial involving an investigational product
Has a positive urine drug test for illicit use of amphetamines, barbiturates, cocaine, methadone, opiates, phencyclidine at screening
